NEW YORK, Dec. 29, 2025 (GLOBE NEWSWIRE) -- Mount Logan Capital Inc. (Nasdaq: MLCI) (“Mount Logan” or the “Company”) today announced that it is commencing a tender offer to purchase for cash up to $15 million of its common stock, par value $0.001, referred to herein as “common stock” or “shares,” or approximately 1,590,600 shares of its common stock (in light of the "round lot" requirement), at a price of $9.43 per share. The closing price of the Company's common stock on December 26, 2025, the last full tr ...

SOLANA BEACH, Calif., and VERO BEACH, Fla., Dec. 17, 2025 /PRNewswire/ -- Evoke Pharma, Inc. (formerlyNASDAQ: EVOK) ("Evoke") and QOL Medical, LLC ("QOL Medical") today announced that the tender offer (the "Offer") by QOL-EOS Merger Sub, Inc., a Delaware corporation and a direct wholly owned subsidiary of QOL Medical (the "Merger Sub"), to acquire all of the outstanding shares of common stock, par value $0.0001 per share (the "Shares"), of Evoke, in exchange for $11.00 in cash per share (the "Offer Price"), ...

Core Viewpoint - Harley-Davidson Financial Services, Inc. has announced the expiration and results of its tender offers for its outstanding Medium-Term Notes, indicating a significant engagement in managing its debt obligations and optimizing its capital structure [1][2]. Summary by Sections Tender Offer Results - The tender offers for the 6.500% Medium-Term Notes due 2028 and 5.950% Medium-Term Notes due 2029 expired on November 21, 2025, with a total of $792,209,000 in aggregate principal amount of Notes validly tendered [1][2]. - This amount excludes $8,090,000 in Notes submitted under the Guaranteed Delivery Procedures [2]. Breakdown of Tendered Notes - For the 2028 Notes, the aggregate principal amount outstanding is $700,000,000, with $437,112,000 tendered and $500,000 reflected in Notices of Guaranteed Delivery [4]. - For the 2029 Notes, the aggregate principal amount outstanding is $500,000,000, with $355,097,000 tendered and $7,590,000 reflected in Notices of Guaranteed Delivery [4]. Consideration and Settlement - The consideration for each $1,000 principal amount of Notes accepted for purchase is $1,055.12 for the 2028 Notes and $1,059.55 for the 2029 Notes, plus accrued interest from the last payment date to the Settlement Date [4][6]. - The Company expects to settle the purchase of all validly tendered Notes on November 24, 2025, and those under Guaranteed Delivery Procedures on November 26, 2025 [6]. Company Overview - Harley-Davidson Financial Services, Inc. is a subsidiary of Harley-Davidson, Inc., primarily engaged in financing and servicing wholesale inventory receivables and retail consumer loans for Harley-Davidson motorcycles [11].

Core Points - Keros Therapeutics, Inc. announced the preliminary results of its cash tender offer to repurchase up to 10,950,165 shares of common stock at a fixed price of $17.75 per share, totaling approximately $194.4 million [1][3] - The tender offer expired on November 18, 2025, and was part of a previously announced $375 million capital return program [1] - A total of approximately 16,659,732 shares were validly tendered, with an additional 1,186,829 shares tendered through notice of guaranteed delivery [2] Tender Offer Details - Keros expects to accept for payment 10,950,165 shares on a pro rata basis due to the oversubscription of shares tendered [3] - The shares to be acquired represent approximately 35.91% of Keros' outstanding common stock as of the expiration date [3] - The final number of shares purchased will be confirmed after the completion of the confirmation process by the Depositary [4] Company Overview - Keros Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel therapeutics targeting disorders linked to dysfunctional signaling of the TGF-ß family of proteins [6] - The company is recognized for its understanding of TGF-ß proteins, which are crucial for the growth and maintenance of various tissues [6] - Keros' lead product candidate, KER-065, targets neuromuscular diseases, particularly Duchenne muscular dystrophy, while its advanced candidate, elritercept, addresses cytopenias in myelodysplastic syndrome and myelofibrosis patients [6]

Core Viewpoint - Harley-Davidson Financial Services, Inc. has initiated tender offers to purchase all Medium-Term Notes issued by the company, aiming to manage its debt obligations effectively [1][2]. Summary by Relevant Sections Tender Offers - The tender offers are made for cash purchases of Medium-Term Notes, with specific details outlined in the Offer to Purchase dated November 17, 2025 [1][2]. - The principal amounts of the Medium-Term Notes include $700 million for 6.500% Notes due 2028 and $500 million for 5.950% Notes due 2029 [2]. Consideration and Terms - The consideration for each $1,000 principal amount of Notes will be determined based on a fixed spread plus the yield to maturity of the applicable U.S. Treasury Reference Security [2]. - The Offers will expire at 5:00 p.m. New York City time on November 21, 2025, unless extended or terminated [2][6]. Settlement and Withdrawal - The expected settlement date for validly tendered Notes is November 24, 2025, with a separate settlement for those tendered through Guaranteed Delivery Procedures expected on November 26, 2025 [4][5]. - Holders can withdraw their tendered Notes at any time before the expiration date, but not thereafter unless required by law [6]. Conditions and Management - The acceptance of Notes for purchase is subject to the satisfaction or waiver of certain conditions set forth in the Offer to Purchase [7]. - The company has the discretion to amend the Offers and extend deadlines as necessary [2][6]. Contact Information - J.P. Morgan, TD Securities, and Wells Fargo Securities are the lead dealer managers for the tender offers, providing assistance to investors [9].

Core Viewpoint - Brunswick Corporation has initiated a tender offer to purchase up to $50 million of its 5.100% Senior Notes due 2052, indicating a strategic move to manage its debt obligations and optimize its capital structure [1][2]. Offer Details - The tender offer will expire at 5:00 p.m. Eastern Time on December 11, 2025, unless extended or terminated earlier by the company [2]. - Tenders can be withdrawn until 5:00 p.m. Eastern Time on November 25, 2025, unless extended [2]. - The total consideration for validly tendered notes will be determined based on a fixed spread over the yield of a specified U.S. Treasury Security, including an early tender premium of $50 per $1,000 principal amount [3][6]. Payment and Settlement - Payments for purchased notes will include accrued and unpaid interest, with the expected early settlement date being December 1, 2025, for notes tendered by the early tender deadline [5][7]. - The settlement date for notes tendered after the early tender deadline is expected to be December 15, 2025 [7]. Tender Conditions - Tenders must be in principal amounts of at least $2,000 and in multiples of $1,000 [4]. - The company reserves the right to adjust the tender cap, which may affect the total amount of notes purchased [10]. - The offer is not subject to a minimum tender condition, but may be subject to proration if the total tendered amount exceeds the tender cap [11][9]. Company Overview - Brunswick Corporation is a leader in marine recreation, offering a wide range of products and services across various brands, including Mercury Marine and Sea Ray [18]. - The company operates globally with approximately 15,000 employees and has been recognized for its workplace culture and innovation [19].

Core Viewpoint - LAVA Therapeutics N.V. is urging its shareholders to tender their shares in the ongoing acquisition offer from XOMA Royalty Corporation before the expiration deadline of November 12, 2025, to avoid potential risks associated with the failure of the transaction [1][3][12]. Group 1: Transaction Details - On August 4, 2025, LAVA and XOMA entered into a share purchase agreement, with XOMA extending its offer to purchase all outstanding common shares of LAVA until November 12, 2025 [2]. - The LAVA Board unanimously recommends that shareholders tender their shares to ensure the completion of the offer [3]. Group 2: Risks of Non-Completion - If the requisite percentage of shares is not tendered, the offer cannot be completed, which may lead to significant risks for shareholders, including potential liquidation and dissolution of LAVA [3][6]. - In the event of non-completion, LAVA's share price may decline, particularly if the current market price reflects expectations of the offer being completed [6]. Group 3: Share Tendering Process - Shareholders holding LAVA shares through brokers are advised to instruct their brokers to tender their shares promptly to meet processing deadlines [4][5]. - Those who have previously tendered their shares do not need to take any further action due to the extension of the offer [8]. Group 4: Company Overview - LAVA Therapeutics is a biopharmaceutical company focused on developing bispecific gamma delta T cell engagers using its proprietary Gammabody® platform, with partnerships including Johnson & Johnson and Pfizer [9].

Core Viewpoint - Taylor Morrison Home Corporation announced the expiration of its cash tender offer for its outstanding 5.875% Senior Notes due 2027, which took place from November 3 to November 7, 2025, with valid tenders amounting to approximately $479.155 million, representing 95.83% of the total outstanding amount of $500 million [1][3][4]. Group 1: Tender Offer Details - The cash tender offer was initiated by Taylor Morrison Communities, Inc., a wholly owned subsidiary of Taylor Morrison Home Corporation [1]. - The expiration time for the tender offer was set for 5:00 p.m. New York City time on November 7, 2025 [1]. - The purchase price for the validly tendered notes was set at $1,023.07 per $1,000 principal amount [3]. Group 2: Financial Implications - The Offeror plans to use a portion of the proceeds from a new issuance of $525 million aggregate principal amount of 5.750% senior notes due 2032 to fund the payment for the notes purchased in the tender offer [4]. - Payment for the validly tendered notes is expected to occur on November 10, 2025 [4]. Group 3: Future Actions - Following the settlement of the tender offer, the Offeror intends to redeem any outstanding notes that were not purchased [5]. - A conditional notice of redemption has been issued for any remaining notes, with a target redemption date around December 2, 2025, contingent upon receiving sufficient funds from the senior notes offering [5]. Group 4: Company Background - Taylor Morrison is recognized as one of the leading homebuilders and developers in the United States, serving a diverse range of consumers across various market segments [8].

Group 1 - Landsbankinn hf. announced a tender offer for its EUR 2027 notes, allowing holders to sell their notes back to the bank for cash [1] - The tender offer is subject to specific terms and conditions outlined in the tender offer memorandum dated 27 October 2025, which includes the outcome of the bank's intended new issuance [1] - Further details regarding the tender offer can be found in the announcement published on Euronext Dublin, where the bonds are listed [2] Group 2 - The tender offer memorandum can be obtained from the tender agent, Kroll Issuer Services Limited, subject to certain distribution restrictions [2] - The joint lead managers for this tender offer include ABN AMRO Bank, BofA Securities Europe, Natixis, and NatWest Markets [2] - This announcement may contain inside information as defined by the Market Abuse Regulation (EU) 596/2014 [3]

Core Points - Novartis announced the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act in relation to its tender offer to acquire Tourmaline Bio at a price of $48.00 per share in cash [1][2] - The expiration of the HSR Act waiting period is a necessary condition for the completion of the merger agreement dated September 8, 2025, which includes the tender offer and subsequent merger [2] - The tender offer will expire at 11:59 p.m. Eastern Time on October 27, 2025, unless extended or terminated earlier [2] Company Information - Novartis is an innovative medicines company focused on improving and extending people's lives through its products, reaching over 300 million people globally [7]